ArticleHuman cell2011
Clinical significance of side population in ovarian cancer cells.
Article in Human cell, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Ivosidenib enhances cisplatin sensitivity in ovarian cancer by reducing cancer cell stemness.Cancer drug resistance (Alhambra, Calif.) · 2025Article
- Article
- A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study.BMC cancer · 2018Article
- Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.Medicines (Basel, Switzerland) · 2018Review
- Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.Molecular oncology · 2016Article
- Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?Oncotarget · 2016Article
- Expression of Multidrug Resistance Transporter ABCB5 in a Murine Model of Human Conjunctival Melanoma.Ocular oncology and pathology · 2015Article
- Reversing paclitaxel resistance in ovarian cancer cells via inhibition of the ABCB1 expressing side population.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Cancer stem-like cell: a novel target for nasopharyngeal carcinoma therapy.Stem cell research & therapy · 2014Review
- Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma.International journal of molecular sciences · 2013Review
- Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma.Human pathology · 2013Review
- Growth inhibition of hepatocellular carcinoma Huh7 cells by Lactobacillus casei extract.Yonsei medical journal · 2013Article
- Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach.Journal of experimental & clinical cancer research : CR · 2013Review
- Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.Molecular cancer · 2013Article
- Ovarian cancer stem cells: a new target for cancer therapy.BioMed research international · 2013Review
- Article
- Ovarian cancer stem cells: elusive targets for chemotherapy.Medical oncology (Northwood, London, England) · 2012Review
- Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary.Journal of ovarian research · 2012Article
- Transformation of epithelial ovarian cancer stemlike cells into mesenchymal lineage via EMT results in cellular heterogeneity and supports tumor engraftment.Molecular medicine (Cambridge, Mass.) · 2012Article
- Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, accumulating evidence has suggested that tumors, including ovarian cancer, are composed of a heterogeneous cell population with a small subset of cancer stem cells (CSCs) that sustain tumor formation and growth. The emergence of drug resistance is one of the most difficult problems in the treatment of ovarian cancer, which has been explained recently by the potential of CSCs to have superior resistance against anti-cancer drugs than conventional cancer cells. In this study, we expanded this line of study to examine whether this phenomenon is also observed in clinical specimens of ovarian cancer cells. In total we could analyze 28 samples out of 60 obtained from ovarian cancer patients. The clinical samples were subjected to testing of the expression of side population (SP) as a CSC marker, and according to the presence of SP (SP+) or absence of SP (SP-), clinicopathological significances were analyzed. Although there was no statistical significance, there were more SP+s in recurrent cases as well as in ascitic and peritoneal dissemination than in primary tumor of the ovary. There was no correlation between SP status and FIGO staging. In 19 cases of those who could be followed more than 6 months from initial therapy, there were 8 cases of recurrence or death from disease, and all of these were SP+. On the other hand, in 11 cases of disease-free survivors, 6 were SP+. There was a significant difference in prognosis between SP+ and SP- (p = 0.017). Although this study was limited, it revealed that SP could be contained more in recurrent or metastatic tumors than in primary tumors, and also that the presence of SP could be a risk factor of recurrence in ovarian cancer. Therefore, a novel therapeutic strategy targeting SP could improve the prognosis of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.